Medications for community pharmacists to dose adjust or avoid to enhance prescribing safety in individuals with advanced chronic kidney disease: a scoping review and modified Delphi – BMC Nephrology

  • Canadian Institute for Health Information. Organ replacement in Canada: CORR annual statistics 2013–2022. Published 2023. Available from: https://www.cihi.ca/en/organ-replacement-in-canada-corr-annual-statistics. Accessed 11 July 2024.

  • Bello AK, Ronksley PE, Tangri N, Kurzawa J, Osman MA, Singer A, Grill A, Nitsch D, Queenan JA, Wick J, Lindeman C, Soos B, Tuot DS, Shojai S, Brimble S, Mangin D, Drummond N. Prevalence and demographics of CKD in Canadian primary care practices: A Cross-sectional Study. Kidney Int Rep. 2019;4(4):561–70.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Secora A, Alexander GC, Ballew SH, et al. Kidney function, polypharmacy, and potentially inappropriate medication use in a community-based cohort of older adults. Drugs Aging. 2018;35(8):735–50.

    Article 
    PubMed 
    PubMed Central 
    CAS 

    Google Scholar
     

  • Lea-Henry TN, Carland JE, Stocker SL, Coresh J, Grams ME. Clinical pharmacokinetics in kidney disease: Fundamental principles. Clin J Am Soc Nephrol. 2018;13(7):1085–95.

    Article 
    PubMed 
    PubMed Central 
    CAS 

    Google Scholar
     

  • Laville SM, Gras-Champel V, Moragny J, Metzger M, Jacquelinet C, Combe C, Fouque D, Laville M, Frimat L, Robinson BM, Stengel B, Massy ZA, Liabeuf S, Chronic Kidney Disease-Renal Epidemiology and Information Network (CKD-REIN) Study Group. Adverse drug reactions in patients with CKD. Clin J Am Soc Nephrol. 2020;15(8):1090–102.

    Article 
    PubMed 
    PubMed Central 
    CAS 

    Google Scholar
     

  • Okpechi IG, Tinwala MM, Muneer S, Zaidi D, Ye F, Hamonic LN, Khan M, Sultana N, Brimble S, Grill A, Klarenbach S, Lindeman C, Molnar A, Nitsch D, Ronksley P, Shojai S, Soos B, Tangri N, Thompson S, Tuot D, Drummond N, Mangin D, Bello AK. Prevalence of polypharmacy and associated adverse health outcomes in adult patients with chronic kidney disease: protocol for a systematic review and meta-analysis. Syst Rev. 2021;10:198.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Quintana-Bárcena P, Lord A, Lizotte A, Berbiche D, Lalonde L. Prevalence and management of drug-related problems in chronic kidney disease patients by severity level: A subanalysis of a cluster randomized controlled trial in community pharmacies. J Manag Care Spec Pharm. 2018;24(2):173–81.

    PubMed 

    Google Scholar
     

  • MacRae C, Mercer S, Guthrie B. Potentially inappropriate primary care prescribing in people with chronic kidney disease: a cross-sectional analysis o f a large population cohort. Br J Gen Pract. 2021;71(708):e483–90.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Ruiz-Boy S, Rodriguez-Reyes M, Clos-Soldevila J, Rovira-Illamola M. Appropriateness of drug prescriptions in patients with chronic kidney disease in primary care: a double-center retrospective study. BMC Prim Care. 2022;23(1):323.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Laville SM, Metzger M, Stengel B, Jacquelinet C, Combe C, Fouque D, Laville M, Frimat L, Ayav C, Speyer E, Robinson BM, Massy ZA, Liabeuf S, Chronic Kidney Disease-Renal Epidemiology and Information Network (CKD-REIN) Study Collaborators. Evaluation of the adequacy of drug prescriptions in patients with chronic kidney disease: results from the CKD-REIN cohort. Br J Clin Pharmacol. 2018;84(12):2811–23.

    Article 
    PubMed 
    PubMed Central 
    CAS 

    Google Scholar
     

  • Tesfaye WH, Castelino RL, Wimmer BC, Zaidi STR. Inappropriate prescribing in chronic kidney disease: A systematic review of prevalence, associated clinical outcomes and impact of interventions. Int J Clin Pract. 2017;71(7):10.

    Article 

    Google Scholar
     

  • By the 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052–2081.

  • Laville SM, Gras-Champel V, Hamroun A, Moragny J, Lambert O, Metzger M, Jacquelinet C, Combe C, Fouque D, Laville M, Frimat L, Robinson BM, Bieber B, Stengel B, De Pinho Alencar N, Massy ZA, Liabeuf S, CKD-REIN Study Group. Kidney function decline and serious adverse drug reactions in patients with CKD. Am J Kidney Dis. 2024;83(5):601–14.

    Article 
    PubMed 
    CAS 

    Google Scholar
     

  • Desrochers JF, Lemieux JP, Morin-Bélanger C, Paradis FS, Lord A, Bell R, Berbiche D, Bárcena PQ, Séguin NC, Desforges K, Legris MÈ, Sauvé P, Lalonde L. Development and validation of the PAIR (Pharmacotherapy Assessment in Chronic Renal Disease) criteria to assess medication safety and use issues in patients with CKD. Am J Kidney Dis. 2011;58(4):527–35.

    Article 
    PubMed 

    Google Scholar
     

  • Tran J, Shaffelburg C, Phelan E, Neville H, Lively A, Poyah P, Tennankore K, More K, Soroka S, Harpell D, Wilson JA. Community pharmacists’ perspectives on assessing kidney function and medication dosing for patients with advanced chronic kidney disease: A qualitative study using the theoretical domains framework. Can Pharm J. 2023;156(5):272–81.

    Article 

    Google Scholar
     

  • Taji L, Battistella M, Grill AK, Cunningham J, Hemmelgarn BL, Quinn KM, Thomas A, Brimble KS. Medications used routinely in primary care to be dose-adjusted or avoided in people with chronic kidney disease: Results of a modified Delphi study. Ann Pharmacother. 2020;54(7):625–32.

    Article 
    PubMed 

    Google Scholar
     

  • Arksey H, O’Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Meth. 2005;8(1):19–32.

    Article 

    Google Scholar
     

  • Levac D, Colquhoun H, O’Brien KK. Scoping studies: Advancing the methodology. Implement Sci. 2010;5:69.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, O’Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Moriarty J, Clifford T, Tunçalp Ö, Straus SE. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and explanation. Ann Intern Med. 2018;169(7):467–73.

    Article 
    PubMed 

    Google Scholar
     

  • Peters M, Casey M, Tricco A, Pollock D, Munn Z, Alexander L, McInerney P, Godfrey CM, Khalil H. Updated methodological guidance for the conduct of scoping reviews. JBI Evid Synth. 2020;18(10):2119–26.

    Article 
    PubMed 

    Google Scholar
     

  • Wilson J, Halliday K, Battistella M, Wazny L, Marin J, Pitman J, Naylor H, Gillis L. High-risk medications commonly used in individuals with chronic kidney disease across primary care settings. Charlottesville, VA: Open Science Framework. Available from:
    https://osf.io/b7jxu. Cited 7 July 2024.

  • McGowan J, Sampson M, Salzwedel D, Cogo E, Foerster V, Lefebvre C. PRESS peer review of electronic search strategies: 2015 guideline statement. J Clinl Epidemiol. 2016;75:40–6.

    Article 

    Google Scholar
     

  • Jünger S, Payne SA, Brine J, Radbruch L, Brearley SG. Guidance on conducting and REporting DElphi Studies (CREDES) in palliative care: Recommendations based on a methodological systematic review. Palliat Med. 2017;31(8):684–706.

    Article 
    PubMed 

    Google Scholar
     

  • Khodyakov D, Grant S, Kroger J, Bauman M. RAND Methodological Guidance for Conducting and Critically Appraising Delphi Panels. [Internet] Santa Monica, CA: RAND Corporation, 2023. Available from: https://www.rand.org/pubs/tools/TLA3082-1.html. Cited 5 July 2024.

  • Opinio (version 7.5). Oslo, Norway: ObjectPlanet Inc.; Copyright 1998–2024 Available from: https://objectplanet.com/opinio/.

  • Schütze A, Benöhr P, Haubitz M, Radziwill R, Hohmann C. Development of a list with renally relevant drugs as a tool to increase medicines optimisation in patients with chronic kidney disease. Eur J Hosp Pharm. 2023;30(1):46–52.

    Article 
    PubMed 

    Google Scholar
     

  • Hamzaei Z, Houlind MB, Kjeldsen LJ, Christensen LWS, Walls AB, Aharaz A, Olesen C, Coric F, Revell JHP, Ravn-Nielsen LV, Andersen TRH, Hedegaard U. Inappropriate prescribing in patients with kidney disease: A rapid review of prevalence, associated clinical outcomes and impact of interventions. Basic Clin Pharmacol Toxicol. 2024;134(4):439–59.

    Article 
    PubMed 
    CAS 

    Google Scholar
     

  • Escribá-Martí G, Cámara-Ramos I, Climent-Catalá MT, Escudero-Quesada V, Salar-Ibáñez L. Pharmaceutical care program for patients with chronic kidney disease in the community pharmacy: Detection of nephrotoxic drugs and dose adjustment Viability Study. PLoS One. 2022;17(12):e0278648.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Mongaret C, Aubert L, Lestrille A, Albaut V, Kreit P, Herlem E, Noel N, Touré F, Lallier F, Slimano F, MIRPhO Investigators Study T. The role of community pharmacists in the detection of clinically relevant drug-related problems in chronic kidney disease patients. Pharmacy (Basel). 2020;8(2):89.

    Article 
    PubMed 

    Google Scholar
     

  • Canadian Pharmacists Association. Pharmacist’s Scope of Practice in Canada. Published October 2023. Available from: https://www.pharmacists.ca/advocacy/scope-of-practice/. Accessed 15 Aug 2024.